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ABSTRACT
Objective To determine the influence of the preoperative
placement of a left ventricular assist device on survival
after heart transplantation.
Design Prospective cohort study.
SettingOrgansharingdatabasewithpatientleveldataon
heart transplants in the United States.
Participants 2786 adults aged 18 or older in status 1A or
1B (highest priority for heart transplantation with either
some form of ventricular assist device, intravenous
inotrope, or life expectancy of less than seven days),
based on the United Network for Organ Sharing Registry,
1996-2004.
Main outcome measure Survival after heart
transplantation in patients who did and did not receive a
left ventricular assist device.
Results The left ventricular assist device was not
associated with decreased survival, even after the data
were stratified by propensity score (the odds of being a
treated patient). Inspection of the strata showed no
difference in survival between patients who received the
deviceandthosewhodidnot.Thehazardratiosinstrata1
to 5 were 0.69, 1.37, 1.55, 0.75, and 1.19, respectively,
and none was statistically significant.
Conclusion Overall, survival after heart transplantation in
patients who received a left ventricular assist device
before transplantation was comparable to those who did
not receive the device.
INTRODUCTION
Transplantcentresworldwidearebeginningtowitness
a plateau in the number of heart transplants as a result
of stabilisation of the donor pool coupled with the
increasing population of patients with end stage heart
failure. Over time a larger proportion of patients wait-
ing for heart transplantation will be bridged with left
ventricular assist devices.
1
A left ventricular assist device is a battery powered,
mechanical pump that is surgically implanted into the
left ventricle and aorta. The device helps maintain the
pumping ability of a heart that cannot work effectively
on its own. The device fills directly from the heart and
pumpsintotheaorta.Severaltypesofdeviceexist,and
since 1996 there have been ongoing improvements in
the design, size, and nature of the pump, with some
providing a pulsatile flow into the aorta and others a
continuous flow. As supportive therapy for patients
with end stage heart failure who are not candidates
for transplants, ventricular assist devices prolong
survival.
1Theroleofthesedevicesasabridgetorecov-
ery or to transplantation has been clearly established
since the late 1990s.
The indication for placement of a left ventricular
assist device in a patient who is a candidate for trans-
plantationisbasedonclinicaldecision,availabilityofa
donor, and adequate psychosocial support. As such
there is inherent selection bias because the use of a
left ventricular assist device as a bridge to heart trans-
plantationisdeterminedbypatientcharacteristics.Itis
knownthatplacementofthe devicebeforehearttrans-
plantation improves clinical and metabolic function at
thetimeoftransplantationandimprovessurvivalwith-
out major complications up to six months after trans-
plantation. Total costs are higher in patients who
receive the device than those who do not, but average
daily costs are similar.
2 Several studies concluded that
the left ventricular assist device improves the survival
of patients after transplantation
34and advocate that it
does not increase the rate of complications. Another
studyconcluded that supportfor the device intensified
the donor shortage by including recipients who would
otherwise have not survived to transplantation.
5 The
implantation of the device favours patients who are
large, have a diagnosis of ischaemic cardiomyopathy,
havehadmultiplebloodtransfusionsandcomplexcar-
diacoperations,and are sensitisedtohuman leucocyte
antigen. Although patients with the device wait longer
for a transplant than those who are classed as status 1
(the highest priority waiting for heart transplantation
and either have some form of ventricular assist device,
intravenous inotrope, or life expectancy of less than
seven days) by the United Network for Organ Sharing
Registry, they have similar post-transplantation hospi-
tal stay, operative mortality, and survival to those not
requiring such support.
5 However, such studies com-
prised small numbers of patients and failed to
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survival of patients classed as status 1 requiring a first
heart transplant who received a left ventricular assist
device with those who did not, adjusting for variation
in case-mix due to possible selection effects.
METHODS
The database of the United Network for Organ Shar-
ing Thoracic Registry includes details of heart, lung,
and heart and lung transplantations carried out in the
United States. The registry has demographic informa-
tion on recipients and donors, ischaemia time, func-
tional status measures, use of intra-aortic balloon
pumps, ventilation after listing, medical comorbidities
(dialysis for renal failure, chronic obstructive pulmon-
ary disease, diabetes, and hypertension), use of a ven-
tricularassistdevice,ABObloodtype,recipientserum
creatinine concentration, recipient serum bilirubin
concentration,geneticcompatibility(humanleucocyte
antigen), cause of donor’s death (anoxia or cerebro-
vascular event or stroke), and cytomegalovirus
infection(presenceofanypositiveresultforcytomega-
lovirus DNA, immunoglobulin G, immunoglobulin
M), and survival.
From among 35898 heart transplantations carried
outonpatientsclassedasstatus1/1A/1B,weidentified
2786 first heart transplantations done between 1996
and 2004 on patients aged 18 and older. We included
patients with Heartmate (XVE Thoratec, CA) or
Novacor(WorldHeart,UT)asabridgedevicetotrans-
plantation. We did not include patients with the
CardioWest (SynCardia Systems, AZ) system in this
analysis as these devices are considered artificial
heart systems. To minimise bias of right ventricular
support we also excluded patients with Thoractec
(Thoratec Laboratories, CA) and other temporary
devices. All patients who received the left ventricular
assist device retained the device until transplantation.
Statistical analysis
We compared baseline characteristics of patients who
did and did not receive a left ventricular assist device,
using two sample t tests for continuous variables and
the χ
2 or Fisher’s exact test for categorical variables.
To control for selection bias we carried out propen-
sity score matching.
6-8 The propensity score or “pro-
pensity score matching” is a general method used to
adjust for selection effects in observational studies,
whether or not randomisation was involved at any
stage in the study. An estimate of the propensity score
is typically obtained by regressing potential confoun-
ders on a binary indicator of treatment received (using
discriminant analysis or logistic regression). The pro-
pensity scoreisthe oddsof beinga treatedpatientcon-
ditional on the potentially confounding variables
alone. The propensity score then may be used as the
basis for stratification of the sample or in matching of
thetreatedandcontrolstudyparticipantsorsometimes
as a covariate in a regression model, although the first
two approaches are less prone to residual bias. Once
matched, bias is eliminated in probability for the set of
covariatesusedinconstructingthepropensityscore.In
our analysis of these data we used propensity score
matchingbasedonalogisticregressionandthecovari-
ates. Patients were assigned to one of five strata. The
first stratum consisted of patients most similar to those
who had a heart transplant but with no previous brid-
ging by device (based on the potential confounders
alone), and the last stratum consisted of patients most
similar to those who had a left ventricular assist device
before heart transplantation (regardless of whether
theyreceivedthedeviceasabridgetotransplantation).
Some of the variables had missing values and so we
imputed those by using the complete sets of observed
values as covariates for prediction purposes.
9 We
Table 1 |Characteristics of patients who did or did not receive a left ventricular assist device
before heart transplantation. Values are numbers (percentages) unless stated otherwise
Variable
Nodevicegroup
(n=1432)
Device group
(n=1354) P value
Sex (female recipient) 333 (23.3) 200 (14.8) <0.001
Mean (SD) recipient age (years) 51.7 (12.6) 50.6 (11.4) 0.01
Mean (SD) recipient body weight (kg) 78.9 (17.0) 86.2 (17.4) <0.001
Race:
African-American 233 (16.3) 200 (14.8) 0.3
Hispanic or Latino 121 (8.5) 51 (3.8) <0.001
Functional status* 1249 (87.2) 1223 (90.3) 0.01
Admitted to hospital for medical condition 938 (65.5) 909 (67.1) 0.4
Ventilator support after listing 74 (5.1) 520 (38.4) <0.001
Transfusion after listing 116 (9.4) 823 (67.9) <0.001
On life support 59 (4.1) 140 (10.3) <0.001
Implantable defibrillator 657 (49.7) 377 (28.8) <0.001
Positive for cytomegalovirus 1112 (77.7) 991 (73.2) 0.006
Medical conditions:
Diabetes 271 (20.0) 291 (22.0) 0.2
Chronic obstructive pulmonary disease 46 (3.4) 42 (3.2) 0.7
Hypertension 477 (36.1) 470 (36.4) 0.9
Dialysis 33 (2.6) 82 (6.3) <0.001
Angina 554 (42.3) 656 (50.2) <0.001
Infection requiring intravenous drug therapy 146 (11.5) 424 (33.4) <0.001
Cerebrovascular disease 40 (3.0) 47 (3.6) 0.4
Peripheral vascular disease 42 (3.2) 43 (3.3) 0.9
Prescribed drugs:
Inotropes 760 (53.1) 708 (52.3) 0.7
Antiarrythmics 498 (39.1) 511 (39.8) 0.7
Amiodarone 441 (33.7) 390 (30.3) 0.07
Primary diagnosis:
Coronary artery disease 37 (2.6) 158 (11.7) <0.001
Cardiovascular disease 1286 (89.8) 1158 (85.5) <0.001
Coronary heart disease 43 (3.0) 4 (0.3) <0.001
Mean (SD) most recent serum creatinine concentration (μmol/l) 123.1 (66.6) 125.7 (65.2) 0.3
Mean (SD) bilirubin concentration (μmol/l) 26.8 (65.5) 19.6 (21.1) <0.001
Haemodynamic data:
Mean (SD) systolic pulmonary artery pressure (mm Hg) 42.6 (13.8) 42.9 (14.4) 0.6
Mean (SD) diastolic pulmonary artery pressure (mm Hg) 20.6 (8.3) 21.7 (9.7) 0.004
Mean (SD) pulmonary artery pressure (mm Hg) 28.7 (10.0) 29.6 (10.6) 0.06
Mean (SD) pulmonary capillary wedge pressure (mm Hg) 19.3 (8.3) 19.9 (9.9) 0.1
Mean (SD) cardiac output (mm Hg) 4.4 (1.6) 4.7 (1.6) <0.001
Mean (SD) active days on waiting list (log) 4.1 (1.7) 4.7 (1.3) <0.001
*Limitations with activities of daily living.
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chain Monte Carlo method, assuming a multivariate
normal distribution for the data. A logistic regression
model was used to develop a propensity score for each
patient for each dataset. We then used the average pro-
pensityscoretoassignpatientsintooneofthefivestrata.
We also carried out a 1:1 propensity score matching
analysis as a sensitivity analysis. To create matched
pairs we used a greedy matching procedure with cali-
pers (width of propensity score intervals) of width 0.2
standard deviations of the logit of the propensity score
andactivedaysonthewaitinglist(≤30daysv>30days).
With this procedure we matched the first randomly
selected patient with a left ventricular assist device to
one without the device, with the closest logit ofthe pro-
pensity score within a specified range (the caliper
width). If several patients without the device were
equallyclosetothepatientwiththedevice,thenweran-
domlyselectedoneofthepatientswithoutthedevicefor
matching to the patient with the device. We repeated
this process until all possible matches were completed.
If no patient without a device was available for a given
Table 2 |Estimates and standard errors for variables included in propensity score analysis
Variable Estimate SE
95% confidence limits
t test P value Lower Upper
Intercept −2.75 0.65 −4.02 −1.48 −4.26 <0.001
Transplant year (after 2000) −1.61 0.20 −2.00 −1.21 −8.01 <0.001
Sex (female recipient) −0.26 0.16 −0.57 0.04 −1.68 0.09
Recipient age (years) −0.01 0.01 −0.02 0.00 −1.68 0.09
Recipient body weight (kg) 0.02 0.00 0.01 0.03 4.90 <0.001
Race:
African-American −0.24 0.16 −0.55 0.07 −1.52 0.1
Hispanic or Latino −0.90 0.25 −1.40 −0.41 −3.60 <0.001
Functional status* 0.93 0.19 0.56 1.30 4.97 <0.001
Admitted to hospital for medical condition −0.25 0.12 −0.49 0.00 −1.98 0.05
Ventilator support after listing 1.72 0.17 1.39 2.05 10.29 <0.001
Transfusion after listing 2.12 0.13 1.85 2.39 15.74 <0.001
On life support 0.63 0.23 0.19 1.07 2.78 0.01
Implantable defibrillator −0.81 0.12 −1.04 −0.57 −6.84 <0.001
Positive for cytomegalovirus −0.22 0.13 −0.47 0.03 −1.69 0.09
Medical conditions:
Hypertension −0.20 0.12 −0.45 0.04 −1.65 0.1
Dialysis −0.27 0.32 −0.90 0.36 −0.85 0.4
Chronic obstructive pulmonary disease −0.37 0.31 −0.98 0.24 −1.19 0.2
Angina 0.06 0.13 −0.19 0.31 0.45 0.7
Diabetes −0.05 0.15 −0.33 0.24 −0.31 0.8
Cerebrovascular disease −0.06 0.33 −0.72 0.60 −0.18 0.8
Peripheral vascular disease 0.08 0.33 −0.57 0.73 0.24 0.8
Prescribed drugs:
Inotrope −0.16 0.12 −0.40 0.07 −1.36 0.2
Infection requiring intravenous drug therapy 0.58 0.17 0.24 0.92 3.43 0.001
Antiarrythmics 0.26 0.16 −0.05 0.57 1.64 0.1
Amiodarone −0.14 0.15 −0.44 0.16 −0.92 0.4
Primary diagnosis:
Coronary artery disease 1.77 0.37 1.03 2.50 4.73 <0.001
Cardiovascular disease 0.34 0.30 −0.25 0.92 1.14 0.3
Coronary heart disease −2.67 0.74 −4.13 −1.21 −3.61 <0.001
Most recent serum creatinine concentration (μmol/l) −0.001 0.001 −0.003 0.001 −1.12 0.3
Bilirubin concentration (μmol/l) −0.006 0.002 −0.01 −0.003 −3.55 <0.001
Haemodynamic data:
Diastolic pulmonary artery pressure (mm Hg) 0.01 0.01 −0.01 0.04 1.12 0.3
Systolic pulmonary artery pressure (mm Hg) −0.02 0.01 −0.04 −0.01 −2.78 0.001
Cardiac output (mm Hg) 0.06 0.04 −0.03 0.15 1.31 0.2
Pulmonary capillary wedge pressure (mm Hg) 0.01 0.01 −0.01 0.04 1.10 0.3
Mean pulmonary artery pressure (mm Hg) 0.03 0.02 0.00 0.06 2.06 0.04
Active days on waiting list (log) 0.24 0.04 0.15 0.32 5.68 <0.001
*Limitations with activities of daily living.
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width, then we excluded the patient with the device
from the matched sample. We also excluded
unmatched patients without the device from the
matchedsample.Thedistributionofeachbaselinechar-
acteristicformatchedsampleshouldbesimilarbetween
the groups. We used standardised differences to exam-
ine the balance of the matched pairs. It has been sug-
gested that a standardised difference of less than 10%
represents meaningful balance.
10
We used the Kaplan-Meier method to compare the
distributions of survival and the log rank test to exam-
ine the differences in survival curves. Risk ratios were
estimated using Cox proportional models, adjusting
for donor related variables that were not included in
the propensity score model (donor’s age, sex, and
weight; ABO blood type match; mismatch of human
leucocyteantigen;ischaemiatime(hours);anddonor’s
cause of death). Data were analysed using SAS 9.13
software for Windows.
Table 3 |Characteristics of participants by propensity score stratum. Values are numbers (percentages) unless stated
otherwise
Variable
Propensity stratum
P value
First
(n=558)
Second
(n=557)
Third
(n=557)
Fourth
(n=557)
Fifth
(n=557)
Sex (female recipient) 184 (33.0) 106 (19.0) 94 (16.9) 82 (14.7) 67 (12.0) <0.001
Mean (SD) recipient age (years) 52.1 (12.6) 52.2 (12.1) 51.2 (11.8) 49.9 (12.2) 50.4 (11.5) 0.003
Mean (SD) recipient body weight (kg) 71.2 (14.6) 81.5 (15.0) 85.0 (17.5) 84.9 (17.6) 89.5 (17.5) <0.001
Race:
African-American 109 (19.5) 81 (14.5) 80 (14.4) 78 (14.0) 85 (15.3) 0.07
Hispanic or Latino 75 (13.4) 33 (5.9) 30 (5.4) 25 (4.5) 9 (1.6) <0.001
Functional status* 463 (83.0) 491 (88.2) 512 (91.9) 503 (90.3) 503 (90.3) <0.001
Admitted to hospital for medical condition 391 (70.1) 335 (60.1) 358 (64.3) 378 (67.9) 385 (69.1) 0.002
Ventilator support after listing 3 (0.5) 11 (2.0) 37 (6.6) 141 (25.3) 402 (72.2) <0.001
Transfusion after listing 9 (1.6) 23 (4.1) 131 (23.5) 368 (66.1) 530 (95.2) <0.001
On life support 14 (2.5) 14 (2.5) 40 (7.2) 44 (7.9) 87 (15.6) <0.001
Implantable defibrillator 351 (62.9) 272 (48.8) 186 (33.4) 177 (31.8) 107 (19.2) <0.001
Positive for cytomegalovirus 456 (81.7) 452 (81.2) 384 (68.9) 388 (69.7) 423 (75.9) <0.001
Medical conditions:
Diabetes 98 (17.6) 120 (21.5) 121 (21.7) 116 (20.8) 130 (23.3) 0.2
Chronic obstructive pulmonary disease 23 (4.1) 14 (2.5) 17 (3.1) 15 (2.7) 19 (3.4) 0.6
Hypertension 191 (34.2) 211 (37.9) 202 (36.3) 208 (37.4) 199 (35.7) 0.7
Dialysis 7 (1.3) 13 (2.3) 17 (3.1) 33 (5.9) 50 (9.0) <0.001
Angina 194 (34.8) 252 (45.2) 259 (46.5) 279 (50.1) 301 (54.0) <0.001
Infection requiring intravenous drug therapy 32 (5.7) 66 (11.9) 109 (19.6) 160 (28.7) 267 (47.9) <0.001
Cerebrovascular disease 15 (2.7) 15 (2.7) 15 (2.7) 18 (3.2) 24 (4.3) 0.5
Peripheral vascular disease 16 (2.9) 17 (3.1) 15 (2.7) 15 (2.7) 22 (4.0) 0.7
Prescribed drugs:
Inotropes 352 (63.1) 279 (50.1) 241 (43.3) 265 (47.6) 331 (59.4) <0.001
Antiarrythmics 208 (37.3) 223 (40.0) 231 (41.5) 204 (36.6) 230 (41.3) 0.3
Amiodarone 204 (36.6) 183 (32.9) 183 (32.9) 164 (29.4) 167 (30.0) 0.08
Primary diagnosis:
Coronary artery disease 0 (0.0) 3 (0.5) 32 (5.6) 55 (9.9) 105 (18.9) <0.001
Cardiovascular disease 483 (86.6) 530 (95.2) 502 (90.1) 485 (87.1) 444 (79.7) <0.001
Coronary heart disease 38 (6.80 5 (0.9) 3 (0.5) 1 (0.2) 0 (0.0) <0.001
Received left ventricular assist device 34 (6.1) 105 (18.9) 240 (43.1) 435 (78.1) 540 (97.0) <0.001
Death 62 (11.1) 71 (12.8) 83 (14.9) 102 (18.3) 123 (22.1) <0.001
Mean (SD) most recent serum creatinine concentration (μmol/l) 121.7(66.2) 125.5(69.2) 127.0(62.2) 126.7(62.6) 130.9(61.0) 0.2
Mean (SD) bilirubin concentration (μmol/l) 37.6 (91.2) 23.6 (27.0) 26.1 (30.9) 24.6 (31.6) 19.0 (18.9) <0.001
Haemodynamic data:
Mean (SD) systolic pulmonary artery pressure (mm Hg) 43.5 (14.5) 45.5 (14.2) 46.7 (14.5) 48.0 (14.5) 50.1 (14.2) <0.001
Mean (SD) diastolic pulmonary artery pressure (mm Hg) 20.9 (8.0) 22.1 (8.1) 23.7 (9.0) 24.6 (8.7) 26.3 (8.8) <0.001
Mean (SD) pulmonary capillary wedge pressure (mm Hg) 19.3 (7.9) 21.2 (8.4) 22.5 (8.8) 23.1 (9.1) 24.9 (8.5) <0.001
Mean (SD) pulmonary artery pressure (mm Hg) 28.7 (9.6) 30.8 (10.0) 32.2 910.8) 33.1 (10.3) 35.0 (10.0) <0.001
Mean (SD) cardiac output (mm Hg) 3.9 (1.3) 4.2 (1.3) 4.2 (1.4) 4.4 (1.5) 4.4 (1.4) <0.001
Mean (SD) active days on waiting list (log) 3.3 (1.6) 4.3 (1.4) 4.6 (1.5) 4.6 (1.4) 4.9 (1.2) <0.001
Patients in fifth stratum were most likely to receive a left ventricular assist device before transplant.
*Limitations with activities of daily living.
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Overall, 1354 patients received a left ventricular assist
device and 1432 did not. Table 1 presents a simple
univariate comparison of pre-transplantation charac-
teristics between these patients. Women were less
likely to receive the device before transplantation
than men. Patients with the device were younger, less
likely to be Hispanic, more likely to be on a ventilator
or life support, more likely to have an infection requir-
ing intravenous drug therapy, less likely to have an
implanted defibrillator, more likely to receive transfu-
sion, and had greater waiting times and higher rates of
dialysis and angina (table 1).
Table 2 presents the variables that were included in
thepropensityscoreanalysis,alongwiththeregression
coefficients and standard errors. Patients were more
likely to receive a left ventricular assist device if they
hadagreaterwaitingtime,alimitationwithactivitiesof
daily living, an infection requiring intravenous drug
therapy, a transfusion, a diagnosis of coronary artery
disease or coronary heart disease, or were on a venti-
lator or life support.
Table 3 presents the results of the propensity score
matching. In general, the higher strata (for example,
strata 4 and 5) were populated with patients who had
characteristics that most resembled those who would
receive a left ventricular assist device. The proportion
ofpatientswhoreceivedthedevicewere6%(34)inthe
first stratum, 19% (105) in the second,43% (240) in the
third, 78% (435) in the fourth, and 97% (540) in the
fifth. The patients in the fifth stratum had an increased
likelihood of being ona ventilator, havingan infection
requiring intravenous drug therapy, receiving transfu-
sion, receiving dialysis, having angina, and being on
life support. The patients in the fifth stratum were
also more likely to be men and less likely to be Hispa-
nic or Latino. The overall proportion of deaths were
11% (62) in the first stratum, 13% (71) in the second,
15% (83) in the third, 18% (102)in the fourth,and 22%
(123) in the fifth.
Overall, the detrimental effects on survival after
transplantation were not significant for patients who
received a left ventricular assist device except in the
third stratum (figure). In that stratum the number of
patients with and without the device was more
balanced (43% v 57%), and a significant difference in
survival was observed. However, the observed differ-
ence in the third stratum was mainly due to a small
number of deaths that occurred in the device group
after five years. Given the lack of overlap between the
two groups in the first and fifth stratum, these results
should be interpreted with care. The analysis of Cox
regression model after adjusting for the donor related
variables also showed no significant difference
between the two groups. Table 4 presents the hazard
ratiosandthe corresponding95%confidenceintervals
within each stratum.
Results of the sensitivity analysis (1:1 propensity
score matching) involved 518 matched pairs (518
patients from each group) for which the matched sam-
ple was well balanced on each variable (data not
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Differences in Kaplan survival distributions between patients
who received a left ventricular assist device and those who
did not within each stratum. Stratum 1=patients most similar
to those who had a heart transplant but no device; stratum
5=patients most similar to those who had a device before
transplantation, with the other three strata being
intermediate in terms of composition
RESEARCH
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in survival between patients who did and did not
receive a left ventricular assist device (log rank
P=0.08; hazard ratio 1.18, 95% confidence interval
0.75 to1.86).
To examine if the difference in the third stratum was
duetotheinfluenceofafewpatientswithlongfollow-up
periods, the analyses were repeated restricting the
observation period to one year and then to five years.
The analysis showed no significant differences in either
shortterm(oneyear)orlongerterm(fiveyear)survival.
Table 5 shows the diagnostic indications for trans-
plantationbetweenpatientswithandwithoutaleftven-
tricular assist device. The most common reason for
transplantation was cardiomyopathy, accounting for
more than 85% of the patients in both groups. Coron-
ary artery disease was more common in the device
group than in the no device group. However, congeni-
tal heart disease and valvular heart disease were more
common in the no device group.
Of the 1354 patients who received a left ventricular
assist device before transplantation, the date of receipt
ofthedevicewasavailablefor957patients.Becausethis
variablewasonlycollectedafter2003,datafortheentire
originalpopulationcould not beanalysed.On average,
time from receipt of the device to transplantation was
147 days (range 0-1240 days). The survival differences
betweenpatientswhoreceivedahearttransplantwithin
30 days of receiving the device and after 30 days were
compared using a log rank test. Survival was similar
between the two groups, indicating no timing effect of
the device on survival after transplantation.
DISCUSSION
In this study we adopted propensity score matching
techniques to compare statistically similar subgroups
of patients with and without left ventricular assist
devices before transplantation—that is, we compared
those patients who received the device with those who
did not within strata of similar baseline characteristics
except for receipt of a device. The survival rate after
transplantation of patients with a left ventricular assist
device was comparable to those without any bridge to
transplantation. Although the log rank test showed a
significant difference in survival in the third stratum
(P=0.045), this was mainly due to the small number of
deaths that occurred after five years in the device
group. At five years survival between the two groups
did not differ.
Overall,wefoundthatsurvivalafterhearttransplan-
tation was not significantly lower for the device group
compared with the no device group. The lack of over-
lap between patients who did and did not receive the
device in the extreme strata (first and fifth) is an inter-
esting result in itself, and points to the high degree of
confounding and selection effects associated with
patientcharacteristicsandthereceiptofa leftventricu-
lar assist device as a bridge to transplantation. This
finding of hidden bias leads us to conclude that it is
all but impossible to provide a simple comparison of
survival between patients who do and do not receive a
leftventricularassistdevice,eitherunadjustedorusing
covariate adjustment in a Cox regression model. This
important methodological observation should help
guide future research in this area.
Comparison with other studies
The decision to implant a ventricular assist device is
based on several indices, including deterioration in
haemodynamic variables or the unsuitability of a can-
didate for transplantation. Initial studies by the Car-
diac Transplant Group and Registry of the
International SocietyforHeartand LungTransplanta-
tion showed that previous mechanical assistance had a
significantly negative effect on survival.
11 This area
remains controversial given recent studies from sev-
eral groups that showed comparable survival. In the
absence of device related complications, optimal per-
fusion of end organs by adequate unloading of the
heart and maximal circulatory support can be
achieved. This provides an improved overall clinical
status of recipients and smoother transition during
transplantation and early recovery. Such patients can
experience a considerable improvement in quality of
life, with return to activities of daily living. One
research team carried out a prospective, multicentre,
non-randomised, controlled study to evaluate the left
ventricular assist device as a bridge to
transplantation.
12 A total of 280 candidates at 24 cen-
treswere treatedwithHeartmate andcomparedwitha
historical control group of 48 patients not supported
withaleftventricularassistdevice.Outcomemeasures
were defined as laboratory data (haemodynamic, hae-
matological, and biochemical), New YorkHeartAsso-
ciation functional class, and survival. The mean
durationofsupportwas112days,with54patientssup-
ported for more than 180 days. A total of 188 patients
(67%) were bridged to transplantation, and 10 (4%)
elected to have the device removed. Of the patients
with the device, 82 (29%) died before transplantation,
compared with 32 (67%) of the 48 control patients.
Complications included bleeding, infection, neurolo-
gical dysfunction, and thromboembolic events. Survi-
val one year after transplantation was significantly
higher in patients in the device group than in those in
the control group: 158 (84%) v 10 (63%).
Thisresultcontrastswithasinglecentreinwhich266
patients classed as status 1 by the United Network for
Organ Sharing were successfully bridged to transplan-
tationbyeithermechanicaldevices(n=121)orinotropic
support (n=145).
13 On the basis of their multivariable
analysis with a Cox proportional hazard model, female
Table 4 |Hazard ratios by propensity score in each stratum
Stratum Variable estimate SE P value Hazard ratio (95% CI)
First −0.371 0.658 0.6 0.69 (0.19 to 2.51)
Second 0.314 0.342 0.4 1.37 (0.70 to 2.68)
Third 0.437 0.311 0.2 1.55 (0.84 to 2.85)
Fourth −0.284 0.358 0.4 0.75 (0.37 to 1.52)
Fifth 0.176 1.014 0.9 1.19 (0.16 to 8.70)
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nificant risk factor as a predictor for decreased survival
after transplantation. Overall, both groups had similar
survivalratesaftertransplantation.However,theresults
ofourpropensityscorematchedstudydonotagreewith
previouslyreportedregistrydatafromtheInternational
Society for Heart and Lung Transplantation, which
have consistently shown the presence of a left ventricu-
lar assist device to be a significant predictor of one year
mortality (odds ratio 1.29; P<0.001) in a multivariable
analysis.
14
Thepropensityscorematchingstrategycarriedoutin
this study goes beyond any of the previously published
reports in terms of adjusting for potential selection
biases that can lead to a false association (or false lack
ofassociation)betweenreceivingaleftventricularassist
deviceandsurvival.Someinvestigatorshaveexamined
the effect of the time interval between placement of the
device and transplantation as a predictor of survival,
with mixed results. One study compared 502 patients
supported witha leftventricular assist devicewith 2514
patients receiving inotropic therapy between 1990 and
1997.
3Theyfoundnodifferencesinsurvivalaftertrans-
plantationdespitecarryingoutmultivariableanalysisto
determine the importance of the time interval for using
the device before transplantation. Another study, how-
ever, found a threefold higher perioperative mortality
amongthosewhoreceivedatransplantlessthan30days
after implantation ofa ventricularassist device, but sur-
vivalatoneyearwassimilar.
4Weexaminedtheeffectof
placement time ofa leftventricular assist device onsur-
vival in a subsample of 957 patients with a known date
of placement. Survival was comparable between
patients who received a transplant within 30 days of
receiving the device and after 30 days suggesting that
the time interval before heart transplantation did not
influence survival.
Immunologicalsensitisationinrecipientsofleftven-
tricular assist devices was observed in this study. The
percentage of panel reactive antibodies before trans-
plantation was higher in the device group than in the
no device group (16.5% v 8.6%; P<0.001). This is in
agreement with other investigators that circulating
antihuman leucocyte antigen class I and II antibodies
occur more commonly in patients with left ventricular
assist devices than in the population not supported by
such devices.
1516
A mild improvement in renal function was seen in
the recipients of a left ventricular assist device.
However, the baseline creatinine concentration was
not significantly elevated in the groups of patients
before transplantation or with the device studied in
this cohort of patients. None the less, a left ventricular
assist device provides effective perfusion to improve
end organ function.
Application of a left ventricular assist device in the
cardiac transplantation population was not evenly dis-
tributedonthebasisofsex,age,andrace.Patientswho
received the device were less likely to be Hispanic and
more likely to be male; white; on a ventilator; have an
infection requiring intravenous drug therapy; have
pre-existing problems of diabetes, hypertension, or
dialysis; to die, and to be significantly younger. These
are important observations to the transplant commu-
nity suggesting further work is needed to tackle this
inequality of healthcare provision, especially when
the Hispanic community is a growing minority in the
United States.
Strengths and limitations of the study
Thecurrentstudyisbasedonalargepopulationcohort
andmanydataentrypointsforvariables.Theresearch
questionwasclearlydefinedwithdistinctinclusionand
exclusion criteria, as well as status on the heart trans-
plantwaitinglist,studyperiod,andtypeofdeviceused,
resulting in a relatively homogeneous study popula-
tion. Variables included in the analysis were compre-
hensive, including those from recipients and donors.
This is a retrospective study, with the limitations
associated with this type of study. Although we
attempted to minimise bias through propensity score
matching, hidden bias could potentially remain
because relevant covariates were not available in the
database of the United Network for Organ Sharing.
Moreover, the database does not provide any data on
peri-transplantmorbiditywithrespecttorejection,pul-
monary hypertension, renal dysfunction, ventilation,
and stay in an intensive care unit. We hope that future
randomised prospective studies will be carried out to
alleviate these potential limitations. Another possible
limitation of the study is that values for missing vari-
ables were imputed using a multiple imputation tech-
nique, which hinges on the assumption of values
missing at random. If the assumption is violated, data
generated by multiple imputation may introduce bias.
Finally, apossible bias might occur if the leftventricu-
lar assist device was associated with increased mortality
during the transplantation itself. This was not the case.
Sixtypatientsdidnotsurvivetheoperation,30ofwhom
receivedthedeviceand30ofwhomdidnot.Allofthese
60 patients were included in the survival analysis.
Conclusions and policy implications
Overall, survival after transplantation did not signifi-
cantlydiffer between the device and nodevice groups.
Inspection of the strata revealed no differences in sur-
vival between the two groups. In those strata within
which the left ventricular assist device was more com-
mon (fourth and fifth), significant differences in survi-
val were not observed.
Table 5 |Diagnostic category for heart transplants. Values are numbers (percentages) unless
stated otherwise
Diagnostic category No device group Device group P value
Not reported 26 (1.8) 15 (1.1) 0.2
Cardiomyopathy 1286 (89.8) 1158 (85.5) <0.001
Coronary artery disease 37 (2.6) 158 (11.7) <0.001
Retransplant or graft failure 0 (0.0) 2 (0.2) 0.2
Valvular heart disease 40 (2.8) 17 (1.3) 0.005
Congenital heart disease 43 (3.0) 4 (0.3) <0.001
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WHAT IS ALREADY KNOWN ON THIS TOPIC
Ventricular assist devices can prolong the life of patients with heart failure before
transplantation
Studies have had mixed results in terms of survival benefit for left ventricular assist devices
WHAT THIS STUDY ADDS
Patientswhoreceivedaleftventricularassistdevicehadsimilarsurvivalaftertransplantation
to those who did not receive the device
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